Media

News Releases 09

DecisionDx-GBM biomarker test for brain cancer now available 04-14-09 Castle Biosciences announces availabilty of DecisonDx-GBM biomarker test for brain cancer (glioblastoma multiforme) patients that predicts overall survival to first-line standard of care treatment

 

News Releases 08

	Brain Cancer Test Option Agreement Announcement 10-07-08 Castle Biosciences signs option agreement for brain cancer (GBM) test with The University of Texas M. D. Anderson Cancer Center
	Maetzold Appointed President and CEO 09-26-08 Derek Maetzold Appointed President and CEO, Castle Biosciences Inc

---

Publications: Related to DecisionDx-GBM

Colman, et al. 2006. Meta-analysis of gene expression profiling data from glioblastoma tumor samples identifies a robust Multigene classifier predictive of survival. Proc Amer Assoc Cancer Res, Volume 47, Abstract # 5688.

Colman, et al. 2007. A robust Multigene classifier predictive of survival in patients with newly diagnosed glioblastoma. Proc Amer Assoc Cancer Res. Vol , Abstract #2700.

Aldape, et al. 2006. Meta-analysis of gene expression profiling data from glioblastoma tumor samples identifies a robust multigene classifier predictive of survival. Journal of the Society for Neuro-Oncology. Abstract GE-01.

 Colman, et al. 2009. A multigene predictor of outcome in glioblastoma. Neuro-Oncology. Advanced Access published, Oct 20, 2009.

Publications: Related to DecisionDx-UM

 Onken, et al. 2004. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64: 7205-9.

 Onken, et al. 2006. Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. Jrnl Mol Diagn; 8: 567-73.

 Worley, et al. 2007. Transcriptomic versus Chromosomal Prognostic Markers and Clinical Outcome in Uveal Melanoma Clin Cancer Res 2007;13(5): 1466-71.